Anticoagulation: Difference between revisions
imported>Robert Badgett |
imported>Robert Badgett |
||
Line 14: | Line 14: | ||
! Stage I or II !! Stage III !! Stage IV | ! Stage I or II !! Stage III !! Stage IV | ||
|- | |- | ||
| rowspan="2"| '''Major<br>bleeding''' || Events per<br>100 patient-years || 8.6 || 3.4 || 19.1 || 42.8 | | rowspan="2"| '''Major<br>bleeding''' || Events per<br>100 patient-years ||align="center"| 8.6 || align="center"|3.4 ||align="center"| 19.1 ||align="center"| 42.8 | ||
|- | |- | ||
| Hazard ratio || 1 || 0.5 || 2.15 || 4.8 | | Hazard ratio ||align="center"| 1 ||align="center"| 0.5 ||align="center"| 2.15 ||align="center"| 4.8 | ||
|- | |- | ||
| rowspan="2"| '''Recurrent<br>VTE''' || Events per<br>100 patient-years || 12.8 || 14.5 || 44.1 || 54.1 | | rowspan="2"| '''Recurrent<br>VTE''' || Events per<br>100 patient-years ||align="center"| 12.8 ||align="center"| 14.5 ||align="center"| 44.1 ||align="center"| 54.1 | ||
|- | |- | ||
| Hazard ratio || 1 || 1.9 || 5.3 || 4.6 | | Hazard ratio ||align="center"| 1 ||align="center"| 1.9 ||align="center"| 5.3 ||align="center"| 4.6 | ||
|- | |- | ||
| colspan="6" align="right"| Adapted from Table 3 of Prandoni et al.<ref name="pmid12393647"/> | | colspan="6" align="right"| Adapted from Table 3 of Prandoni et al.<ref name="pmid12393647"/> |
Revision as of 20:02, 2 January 2008
The metadata subpage is missing. You can start it via filling in this form or by following the instructions that come up after clicking on the [show] link to the right. | |||
---|---|---|---|
|
Adverse effects
Patients aged 80 years or more may be especially susceptible to bleeding complications with a rate of 13 bleeds per 100 person-years.[1]
Patients with cancer are more likely to have bleeding complications, especially if they have Stage III (regionally extensive) or IV (metastatic) cancer.[2] Regardless of the extent of cancer, the risk of bleeding was less than the risk of recurrent embolism and thromboembolism:
No cancer | Cancer | ||||
---|---|---|---|---|---|
Stage I or II | Stage III | Stage IV | |||
Major bleeding |
Events per 100 patient-years |
8.6 | 3.4 | 19.1 | 42.8 |
Hazard ratio | 1 | 0.5 | 2.15 | 4.8 | |
Recurrent VTE |
Events per 100 patient-years |
12.8 | 14.5 | 44.1 | 54.1 |
Hazard ratio | 1 | 1.9 | 5.3 | 4.6 | |
Adapted from Table 3 of Prandoni et al.[2] |
References
- ↑ Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S (2007). "Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation". Circulation 115 (21): 2689-96. DOI:10.1161/CIRCULATIONAHA.106.653048. PMID 17515465. Research Blogging. PMID 17515465
- ↑ 2.0 2.1 Prandoni P, Lensing AW, Piccioli A, et al (2002). "Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis". Blood 100 (10): 3484–8. DOI:10.1182/blood-2002-01-0108. PMID 12393647. Research Blogging.
See also
External links
The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines